Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: An immunohistochemical and fluorescence in situ hybridization pilot study

R. Caltabiano, G. M V Barbagallo, M. Castaing, A. Cassenti, R. Senetta, P. Cassoni, V. Albanese, S. Lanzafame

Research output: Contribution to journalArticle

Abstract

Aim. The aim of this study was to assess both the epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry and the EGFR gene amplification by fluorescence in situ hybridization in meningiomas of different grade, in order to evaluate their possible role in the development of the disease. EGFR protein belongs to the family of tyrosine kinase growth factor receptors, which also includes HER2, HER3 and HER4. Elevated expression or activity of EGFR has been reported in several cancers, including brain tumours. EGFR activation can enhance the malignant potential of epithelial tissues. Methods. We investigated whether there was a difference in the EGFR protein expression and the EGFR gene amplification between the so called de novo malignant meningiomas and recurrent meningiomas with or without malignant progression from a previously lower grade tumor. Our goal was to evaluate if EGFR expression was a useful marker to select patients affected by meningioma with a major risk of recurrences. We also assessed the prognostic value of the EGFR expression on overall survival. Results. Progression from benign meningiomas to atypical or anaplastic meningiomas correlated with an increase in the expression of EGFR protein. Our study shows that EGFR immunostaining in meningiomas directly correlates to the tumor's grade. The EGFR expression did not correlate with the overall survival and the recurrence-free survival of the patients affected by meningioma (de novo, recurrent and progressed). Conclusion. We submit that the EGFR expression is not a useful prognostic element to identify patients with a major risk of meningioma recurrence.

Original languageEnglish
Pages (from-to)139-151
Number of pages13
JournalJournal of Neurosurgical Sciences
Volume57
Issue number2
Publication statusPublished - Jun 2013

Fingerprint

Meningioma
Fluorescence In Situ Hybridization
Epidermal Growth Factor Receptor
erbB-1 Genes
Gene Amplification
Recurrence
Brain Neoplasms
Survival
Proteins
Growth Factor Receptors
Protein-Tyrosine Kinases
Neoplasms
Epithelium
Immunohistochemistry

Keywords

  • Immunohistochemistry
  • In situ hybridization, fluorescence
  • Meningioma
  • Receptor, epidermal growth factor

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Caltabiano, R., Barbagallo, G. M. V., Castaing, M., Cassenti, A., Senetta, R., Cassoni, P., ... Lanzafame, S. (2013). Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: An immunohistochemical and fluorescence in situ hybridization pilot study. Journal of Neurosurgical Sciences, 57(2), 139-151.

Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas : An immunohistochemical and fluorescence in situ hybridization pilot study. / Caltabiano, R.; Barbagallo, G. M V; Castaing, M.; Cassenti, A.; Senetta, R.; Cassoni, P.; Albanese, V.; Lanzafame, S.

In: Journal of Neurosurgical Sciences, Vol. 57, No. 2, 06.2013, p. 139-151.

Research output: Contribution to journalArticle

Caltabiano, R, Barbagallo, GMV, Castaing, M, Cassenti, A, Senetta, R, Cassoni, P, Albanese, V & Lanzafame, S 2013, 'Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: An immunohistochemical and fluorescence in situ hybridization pilot study', Journal of Neurosurgical Sciences, vol. 57, no. 2, pp. 139-151.
Caltabiano, R. ; Barbagallo, G. M V ; Castaing, M. ; Cassenti, A. ; Senetta, R. ; Cassoni, P. ; Albanese, V. ; Lanzafame, S. / Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas : An immunohistochemical and fluorescence in situ hybridization pilot study. In: Journal of Neurosurgical Sciences. 2013 ; Vol. 57, No. 2. pp. 139-151.
@article{68e42f54843a439d98f4d1ba2f04d8b5,
title = "Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: An immunohistochemical and fluorescence in situ hybridization pilot study",
abstract = "Aim. The aim of this study was to assess both the epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry and the EGFR gene amplification by fluorescence in situ hybridization in meningiomas of different grade, in order to evaluate their possible role in the development of the disease. EGFR protein belongs to the family of tyrosine kinase growth factor receptors, which also includes HER2, HER3 and HER4. Elevated expression or activity of EGFR has been reported in several cancers, including brain tumours. EGFR activation can enhance the malignant potential of epithelial tissues. Methods. We investigated whether there was a difference in the EGFR protein expression and the EGFR gene amplification between the so called de novo malignant meningiomas and recurrent meningiomas with or without malignant progression from a previously lower grade tumor. Our goal was to evaluate if EGFR expression was a useful marker to select patients affected by meningioma with a major risk of recurrences. We also assessed the prognostic value of the EGFR expression on overall survival. Results. Progression from benign meningiomas to atypical or anaplastic meningiomas correlated with an increase in the expression of EGFR protein. Our study shows that EGFR immunostaining in meningiomas directly correlates to the tumor's grade. The EGFR expression did not correlate with the overall survival and the recurrence-free survival of the patients affected by meningioma (de novo, recurrent and progressed). Conclusion. We submit that the EGFR expression is not a useful prognostic element to identify patients with a major risk of meningioma recurrence.",
keywords = "Immunohistochemistry, In situ hybridization, fluorescence, Meningioma, Receptor, epidermal growth factor",
author = "R. Caltabiano and Barbagallo, {G. M V} and M. Castaing and A. Cassenti and R. Senetta and P. Cassoni and V. Albanese and S. Lanzafame",
year = "2013",
month = "6",
language = "English",
volume = "57",
pages = "139--151",
journal = "Journal of Neurosurgical Sciences",
issn = "0026-4881",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas

T2 - An immunohistochemical and fluorescence in situ hybridization pilot study

AU - Caltabiano, R.

AU - Barbagallo, G. M V

AU - Castaing, M.

AU - Cassenti, A.

AU - Senetta, R.

AU - Cassoni, P.

AU - Albanese, V.

AU - Lanzafame, S.

PY - 2013/6

Y1 - 2013/6

N2 - Aim. The aim of this study was to assess both the epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry and the EGFR gene amplification by fluorescence in situ hybridization in meningiomas of different grade, in order to evaluate their possible role in the development of the disease. EGFR protein belongs to the family of tyrosine kinase growth factor receptors, which also includes HER2, HER3 and HER4. Elevated expression or activity of EGFR has been reported in several cancers, including brain tumours. EGFR activation can enhance the malignant potential of epithelial tissues. Methods. We investigated whether there was a difference in the EGFR protein expression and the EGFR gene amplification between the so called de novo malignant meningiomas and recurrent meningiomas with or without malignant progression from a previously lower grade tumor. Our goal was to evaluate if EGFR expression was a useful marker to select patients affected by meningioma with a major risk of recurrences. We also assessed the prognostic value of the EGFR expression on overall survival. Results. Progression from benign meningiomas to atypical or anaplastic meningiomas correlated with an increase in the expression of EGFR protein. Our study shows that EGFR immunostaining in meningiomas directly correlates to the tumor's grade. The EGFR expression did not correlate with the overall survival and the recurrence-free survival of the patients affected by meningioma (de novo, recurrent and progressed). Conclusion. We submit that the EGFR expression is not a useful prognostic element to identify patients with a major risk of meningioma recurrence.

AB - Aim. The aim of this study was to assess both the epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry and the EGFR gene amplification by fluorescence in situ hybridization in meningiomas of different grade, in order to evaluate their possible role in the development of the disease. EGFR protein belongs to the family of tyrosine kinase growth factor receptors, which also includes HER2, HER3 and HER4. Elevated expression or activity of EGFR has been reported in several cancers, including brain tumours. EGFR activation can enhance the malignant potential of epithelial tissues. Methods. We investigated whether there was a difference in the EGFR protein expression and the EGFR gene amplification between the so called de novo malignant meningiomas and recurrent meningiomas with or without malignant progression from a previously lower grade tumor. Our goal was to evaluate if EGFR expression was a useful marker to select patients affected by meningioma with a major risk of recurrences. We also assessed the prognostic value of the EGFR expression on overall survival. Results. Progression from benign meningiomas to atypical or anaplastic meningiomas correlated with an increase in the expression of EGFR protein. Our study shows that EGFR immunostaining in meningiomas directly correlates to the tumor's grade. The EGFR expression did not correlate with the overall survival and the recurrence-free survival of the patients affected by meningioma (de novo, recurrent and progressed). Conclusion. We submit that the EGFR expression is not a useful prognostic element to identify patients with a major risk of meningioma recurrence.

KW - Immunohistochemistry

KW - In situ hybridization, fluorescence

KW - Meningioma

KW - Receptor, epidermal growth factor

UR - http://www.scopus.com/inward/record.url?scp=84879594759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879594759&partnerID=8YFLogxK

M3 - Article

C2 - 23486338

AN - SCOPUS:84879594759

VL - 57

SP - 139

EP - 151

JO - Journal of Neurosurgical Sciences

JF - Journal of Neurosurgical Sciences

SN - 0026-4881

IS - 2

ER -